-
21 Octobre 2021
-
08 Juin 2020
Ipsen réaffirme son engagement dans les maladies rares avec la publication de huit abstracts acceptés lors de l’ENDO 2020 et publiés dans le Journal of the Endocrine Society
Les données publiées évaluent la progression naturelle de la fibrodysplasieossifiante progressive (FOP) ou de l’acromégalieLa Natural History Study (NHS) est la première étude longitudinale définiepar protocole destinée à évaluer la progressi...
-
26 Mars 2020
-
22 Avril 2020
Ipsen reports solid sales growth in first quarter 2020 with limited COVID-19 impact
Paris (France), 22 April 2020 – Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2020....
-
26 Juillet 2021
-
13 Février 2020
Ipsen presents its 2019 results, provides 2020 guidance and updates 2022 financial outlook
Aymeric Le Chatelier, Chief Executive Officer and Chief Financial Officer of Ipsen, stated: “2019 was another excellent year of operating performance for Ipsen with continued double-digit top-line growth and core operating margin expansion. Despite the ...
-
30 Juillet 2020
Ipsen presents its half year 2020 results and reinstates guidance for full year 2020
David Loew, Chief Executive Officer of Ipsen, stated: “I’m honored since July 1st to lead Ipsen, an exciting global biopharma business with solid business fundamentals, a strong purpose to serve patients and attractive growth opportunities. I am enco...
-
24 Janvier 2020
-
16 Octobre 2019
Ipsen and Blueprint Medicines announce exclusive global license agreement to develop and commercialize BLU-782 for the treatment of fibrodysplasia ossificans progressiva (FOP)
— Expands Ipsen’s Rare Diseases portfolio to include BLU-782,a highly selective investigational ALK2 inhibitor for the treatment of FOP —— Accelerates global development of BLU-782 through Ipsen’s clinical expertisein rare diseases and global i...
-
06 Décembre 2019
Ipsen Initiates Partial Clinical Hold for Palovarotene IND120181 and IND135403 Studies
PARIS, France, 6 December 2019 — Ipsen (Euronext: IPN; ADR: IPSEY) today announced, following discussions with the U.S. Food and Drug Administration (FDA), that a partial clinical hold effective immediately, for the pediatric population under the age o...